

STATE OF CONNECTICUT


DEPARTMENT OF PUBLIC HEALTH

Manisha Juthani, MD
Commissioner



Ned Lamont
Governor
Susan Bysiewicz
Lt. Governor

Immunization Program

TO: All CVP Providers
FROM: Mick Bolduc 
Vaccine Coordinator-Connecticut Vaccine Program (CVP)
DATE: November 3, 2022
SUBJECT: New Vaccines Available

The primary purpose of this communication is to notify providers of 2 new vaccines that will be available through the CVP starting on December 1, 2022.

New MMR Vaccine

On December 1st the CVP will begin offering Priorix[®] measles, mumps, and rubella (MMR) combination vaccine manufactured by Glaxo SmithKline. Priorix[®] is stored in the refrigerator and packaged in a box of 10 single dose vials. Priorix[®] is licensed for ages 12 months of age and older: dose one at 12–15 months of age; dose two at 4 through 6 years of age.

Priorix[®] can be administered as a second dose to individuals who have received a first dose of another MMR containing vaccine. See the full prescribing information for Priorix here: [PRIORIX \(gskpro.com\)](http://PRIORIX(gskpro.com)). Providers who want to switch to Priorix[®] should use up or transfer remaining doses of Merck's MMR vaccine to avoid wastage.

New PCV Vaccine

On December 1st the CVP will begin offering Vaxneuvance[®] Pneumococcal 15-valent Conjugate vaccine manufactured by Merck. Vaxneuvance[®] is stored in the refrigerator and packaged in a box of 10 single dose syringes. Vaxneuvance[®] is licensed for a four-dose series at 2, 4, 6 and 12–15 months of age. See the full prescribing information for Vaxneuvance here: [vaxneuvance_pi \(merck.com\)](http://vaxneuvance_pi(merck.com)).

Vaxneuvance[®] can be used to complete a series started with Pfizer's PCV13. Providers who want to switch to Vaxneuvance[®] should use up or transfer remaining doses of Pfizer's PCV13 vaccine to avoid wastage.

As always, if you have any questions, please feel free to contact the CVP at (860) 509-7929.



Phone: (860) 509-7929 • Fax: (860) 706-5429
Telecommunications Relay Service 7-1-1
410 Capitol Avenue, P.O. Box 340308
Hartford, Connecticut 06134-0308
<https://portal.ct.gov/dph>

Affirmative Action/Equal Opportunity Employer



Connecticut Vaccine Program (CVP) Eligibility Criteria as of December 1, 2022

Vaccine	Age Group	Status of Children VFC and State Supplied Vaccine				CPT Code(s)
		VFC Eligible ¹	Non-VFC Eligible Privately Insured ²	Non-VFC Eligible Under- Insured ²	S-CHIP ²	
Hepatitis B	Newborns in hospital	YES	YES	YES	YES	90744
	Children 0-18 years	YES	YES	YES	YES	
Varicella (Doses 1 & 2)	12 months-18 years ³	YES	YES	YES	YES	90716
Td	7-18 years ⁴	YES	YES	YES	YES	90714
MMR	12 months-18 years	YES	YES	YES	YES	90707
	College (any age)	YES	YES	YES	YES	
MMRV (Doses 1 & 2)	12 months-12 years	YES	YES	YES	YES	90710
DTaP	2 months – 6 years	YES	YES	YES	YES	90700
Hib	2-59 months	YES	YES	YES	YES	90647, 90648
IPV	2 months-18 years	YES	YES	YES	YES	90713
DTaP/IPV	4-6 years	YES	YES	YES	YES	90696
DTaP/IPV/Hep B	2-83 months	YES	YES	YES	YES	90723
DTaP/IPV/Hib	2-59 months	YES	YES	YES	YES	90698
DTaP/IPV/Hib/Hep B	2-59 months	YES	YES	YES	YES	90697
Meningococcal Conjugate High Risk:	2 months-10 years	YES	YES	YES	YES	90619, 90734
Routine Doses 1 & 2:	11-18 years	YES	YES	YES	YES	
Tdap	7-18 years ⁵	YES	YES	YES	YES	90715
Pneumococcal Conjugate 13	2 months-18 years	YES	YES	YES	YES	90670
Pneumococcal Polysaccharide (PPSV23)	2-18 years	YES	YES	YES	YES	90732
Influenza	6 months-18 years	YES	YES	YES	YES	90672, 90674, 90686
Hepatitis A	12 months -18 years	YES	YES	YES	YES	90633
Rotavirus	6 weeks-8 months	YES	YES	YES	YES	90680, 90681
HPV (males & females)	9-10 & 13-18 years	YES	NO	YES	YES	90651
	11-12 years	YES	YES	YES	YES	
Meningococcal Serogroup B High Risk:	10-18 years	YES	YES	YES	YES	90620, 90621
Routine Doses 1 & 2:	16-18 years	YES	YES	YES	YES	
Pneumococcal Conjugate 15	2 months-18 years	YES	YES	YES	YES	90671

- VFC eligibility is defined as follows: (a) Medicaid enrolled; (b) NO health insurance; (c) American Indian or Alaskan native; or (d) underinsured seen at an FQHC.
- Non-VFC children refers to patients who have private insurance that covers the cost of immunizations, patients that are under-insured for some or all vaccines seen by a private provider; and S-CHIP children- those children enrolled in HUSKY B.
- Susceptible children who do not have a clinical history of chicken pox.
- Td vaccine can be given to children 7-18 years of age to complete their primary series, or to those children 7-18 years of age who are in need of a Tetanus containing vaccine and cannot receive Tdap.
- Tdap vaccine should be administered routinely to children at the 11-12 year old preventive health care visit, and to children 7-10 & 13-18 years old who have not been fully vaccinated against pertussis and for whom no contraindication to pertussis containing vaccine exists.

As of July 1, 2020 the only childhood vaccine not universally available from the CVP is HPV for privately insured patients 9-10 & 13-18 years of age. Providers can purchase this vaccine privately and submit billing requests to the appropriate insurer in accordance with normal billing procedures.